Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo.
CYP haplotypes
Pharmacogenomics
Pharmacokinetic modelling
Precision dosing
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
received:
22
03
2024
accepted:
23
06
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
4
7
2024
Statut:
aheadofprint
Résumé
The CYP2D6 gene exhibits significant polymorphism, contributing to variability in responses to drugs metabolized by CYP2D6. While CYP2D6*2 and CYP2D6*35 are presently designated as alleles encoding normal metabolism, this classification is based on moderate level evidence. Additionally, the role of the formerly called "enhancer" single nucleotide polymorphism (SNP) rs5758550 is unclear. In this study, the impacts of CYP2D6*2, CYP2D6*35 and rs5758550 on CYP2D6 activity were investigated using risperidone clearance as CYP2D6 activity marker. A joint parent-metabolite population pharmacokinetic model was used to describe 1,565 serum concentration measurements of risperidone and 9-hydroxyrisperidone in 512 subjects. Risperidone population clearance was modeled as the sum of a CYP2D6-independent clearance term and the partial clearances contributed from each individually expressed CYP2D6 allele or haplotype. In addition to the well-characterized CYP2D6 alleles (*3-*6, *9, *10 and *41), *2, *35 and two haplotypes assigned as CYP2D6*2-rs5758550G and CYP2D6*2-rs5758550A were evaluated. Each evaluated CYP2D6 allele was associated with significantly lower risperidone clearance than the reference normal function allele CYP2D6*1 (p < 0.001). Further, rs5758550 differentiated the effect of CYP2D6*2 (p = 0.005). The haplotype-specific clearances for CYP2D6*2-rs5758550A, CYP2D6*2-rs5758550G and CYP2D6*35 were estimated to 30%, 66% and 57%, respectively, relative to the clearance for CYP2D6*1. Notably, rs5758550 is in high linkage disequilibrium (R CYP2D6*2 and CYP2D6*35 encode reduced risperidone clearance, and the extent of reduction for CYP2D6*2 is differentiated by rs5758550. Genotyping of these haplotypes might improve the precision of genotype-guided prediction of CYP2D6-mediated clearance.
Identifiants
pubmed: 38963454
doi: 10.1007/s00228-024-03721-6
pii: 10.1007/s00228-024-03721-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The Swedish Research Council
ID : 2021-02801
Organisme : The Swedish Research Council
ID : 2021-02801
Informations de copyright
© 2024. The Author(s).
Références
Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48(11):689–723
pubmed: 19817501
doi: 10.2165/11318030-000000000-00000
Taylor C et al (2020) A review of the important role of CYP2D6 in pharmacogenomics. Genes (Basel) 11(11):1295
Caudle KE et al (2020) Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci 13(1):116–124
pubmed: 31647186
doi: 10.1111/cts.12692
Clinical Pharmacogenetics Implementation Consortium (CPIC
van der Lee M, Guchelaar HJ, Swen JJ (2021) Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics 22(16):1081–1089
pubmed: 34569808
doi: 10.2217/pgs-2021-0093
Hertz DL et al (2015) In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol 80(5):1122–1130
pubmed: 25907378
pmcid: 4631184
doi: 10.1111/bcp.12665
Abduljalil K et al (2010) Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 88(5):643–651
pubmed: 20881950
doi: 10.1038/clpt.2010.137
Sehrt D et al (2011) Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 12(6):783–795
pubmed: 21599570
doi: 10.2217/pgs.11.20
Frederiksen T et al (2023) Estimating the in vivo function of CYP2D6 alleles through population pharmacokinetic modeling of brexpiprazole. Clin Pharmacol Ther 113(2):360–369
pubmed: 36350097
doi: 10.1002/cpt.2791
Frederiksen T et al (2021) Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through population pharmacokinetic analysis of vortioxetine. Clin Pharmacol Ther 109(1):150–159
pubmed: 32599653
doi: 10.1002/cpt.1972
Frederiksen T et al (2021) Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine. CPT Pharmacometrics Syst Pharmacol 10(9):983–993
pubmed: 33932135
pmcid: 8452298
doi: 10.1002/psp4.12635
Muroi Y et al (2014) Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity. Drug Metab Pharmacokinet 29(5):360–366
pubmed: 24647041
doi: 10.2133/dmpk.DMPK-14-RG-014
Pratt VM et al (2021) Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. J Mol Diagn 23(9):1047–1064
pubmed: 34118403
pmcid: 8579245
doi: 10.1016/j.jmoldx.2021.05.013
Wang D et al (2014) Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet 23(1):268–278
pubmed: 23985325
doi: 10.1093/hmg/ddt417
Wang D, Papp AC, Sun X (2015) Functional characterization of CYP2D6 enhancer polymorphisms. Hum Mol Genet 24(6):1556–1562
pubmed: 25381333
doi: 10.1093/hmg/ddu566
Ray B et al (2019) CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels. Pharmacogenet Genomics 29(2):39–47
pubmed: 30520769
pmcid: 6441960
doi: 10.1097/FPC.0000000000000363
Dinh JC et al (2022) The impact of the CYP2D6 “enhancer” single nucleotide polymorphism on CYP2D6 activity. Clin Pharmacol Ther 111(3):646–654
pubmed: 34716917
doi: 10.1002/cpt.2469
Sanchez-Spitman AB et al (2017) The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. Pharmacogenomics 18(12):1125–1132
pubmed: 28745555
doi: 10.2217/pgs-2017-0080
Zanger UM et al (2021) Tri-allelic haplotypes determine and differentiate functionally normal allele CYP2D6*2 and impaired allele CYP2D6*41. Clin Pharmacol Ther 109(5):1256–1264
pubmed: 33043448
doi: 10.1002/cpt.2078
Løvlie R et al (2001) Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11(1):45–55
pubmed: 11207030
doi: 10.1097/00008571-200102000-00006
Allorge D et al (2001) In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics 11(8):739–41
pubmed: 11692084
doi: 10.1097/00008571-200111000-00014
Saito T et al (2018) Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation. Drug Metab Pharmacokinet 33(6):250–257
pubmed: 30366777
doi: 10.1016/j.dmpk.2018.08.004
Jukic MM et al (2019) Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry 6(5):418–426
pubmed: 31000417
doi: 10.1016/S2215-0366(19)30088-4
Zhang L et al (2020) CYP2D6 genetic polymorphisms and risperidone pharmacokinetics: a systematic review and meta-analysis. Pharmacotherapy 40(7):632–647
pubmed: 32519344
doi: 10.1002/phar.2434
Hiemke C et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1–02):9–62
pubmed: 28910830
Irby DJ et al (2021) Approaches to handling missing or “problematic” pharmacology data: pharmacokinetics. CPT Pharmacometrics Syst Pharmacol 10(4):291–308
pubmed: 33715307
pmcid: 8099444
doi: 10.1002/psp4.12611
Keizer RJ et al (2015) Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect 3(2):e00131
pubmed: 26038706
pmcid: 4448983
doi: 10.1002/prp2.131
Lenk H et al (2023) Impact of NFIB and CYP1A variants on clozapine serum concentration-a retrospective naturalistic cohort study on 526 patients with known smoking habits. Clin Transl Sci 16(1):62–72
pubmed: 36152308
doi: 10.1111/cts.13422
Lenk HC et al (2022) The polymorphic nuclear factor NFIB regulates hepatic CYP2D6 expression and influences risperidone metabolism in psychiatric patients. Clin Pharmacol Ther 111(5):1165–1174
pubmed: 35253216
pmcid: 9314634
doi: 10.1002/cpt.2571
Mulder TAM et al (2021) CYP3A4(∗)22 Genotyping in clinical practice: ready for implementation? Front Genet 12:711943
pubmed: 34306041
pmcid: 8296839
doi: 10.3389/fgene.2021.711943
Korell J et al (2017) Determination of plasma concentration reference ranges for risperidone and paliperidone. CPT Pharmacometrics Syst Pharmacol 6(9):589–595
pubmed: 28614899
pmcid: 5613178
doi: 10.1002/psp4.12217
Ahlers SJ et al (2015) Morphine glucuronidation and elimination in intensive care patients: a comparison with healthy volunteers. Anesth Analg 121(5):1261–1273
pubmed: 26332855
doi: 10.1213/ANE.0000000000000936
Jonsson EN, Karlsson MO (1998) Automated covariate model building within NONMEM. Pharm Res 15(9):1463–1468
pubmed: 9755901
doi: 10.1023/A:1011970125687
Bergstrand M et al (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143–151
pubmed: 21302010
pmcid: 3085712
doi: 10.1208/s12248-011-9255-z
Efron B (1979) Bootstrap methods: another look at the jackknife. Ann Stat 7:1–26
doi: 10.1214/aos/1176344552
Pirana LP. 100 Overlook Center, Suite 101. Princeton, NJ, 08540 USA
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/
Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85–94
pubmed: 15212851
doi: 10.1016/j.cmpb.2003.11.003
Machiela MJ, Chanock SJ (2015) LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31(21):3555–3557
pubmed: 26139635
pmcid: 4626747
doi: 10.1093/bioinformatics/btv402
Thomas CD et al (2020) Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype-derived activity scores. CPT Pharmacometrics Syst Pharmacol 9(12):678–685
pubmed: 33067866
pmcid: 7762806
doi: 10.1002/psp4.12563
Khor CC et al (2023) Cross-ancestry genome-wide association study defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations. Clin Pharmacol Ther 113(3):712–723
pubmed: 36629403
doi: 10.1002/cpt.2846
Jukic MM et al (2021) Evaluation of the CYP2D6 haplotype activity scores based on metabolic ratios of 4,700 patients treated with three different CYP2D6 substrates. Clin Pharmacol Ther 110(3):750–758
pubmed: 33792048
doi: 10.1002/cpt.2246
Vandenberghe F et al (2015) Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet 54(12):1259–1272
pubmed: 26129906
doi: 10.1007/s40262-015-0289-8
Feng Y et al (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 66(5):629–639
pubmed: 18771484
pmcid: 2661978
doi: 10.1111/j.1365-2125.2008.03276.x
Thyssen A et al (2010) Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet 49(7):465–478
pubmed: 20528007
doi: 10.2165/11531730-000000000-00000
van der Burgh AC et al (2021) Determinants of the evolution of kidney function with age. Kidney Int Rep 6(12):3054–3063
pubmed: 34901574
pmcid: 8640542
doi: 10.1016/j.ekir.2021.10.006
Schlatter C et al (2009) Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf 32(7):561–578
pubmed: 19530743
doi: 10.2165/00002018-200932070-00003
Beunk L et al (2023) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet 32(3):278–285